Lombard Medical, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company reported Revenues were $2.400 million against $2.943 million a year ago. Operating loss was $4.143 million against $11.920 million a year ago. Loss before income taxes was $8.597 million against $12.169 million a year ago. Loss for the period was $7.69 million against $11.605 million a year ago. Basic and diluted loss per ordinary share from continuing operations were $0.37 against $0.58 a year ago.

For the year, the company reported Revenues were $12.169 million against $15.114 million a year ago. The year-over-year reduction in revenue is primarily attributable to the redeployment of commercial resources from the US to Europe to support the launch of the Altura endovascular stent graft along with delayed stocking orders from the company's Japanese distribution partner as it prepared for approval and launch of the IntelliFlex LP delivery system in early 2017. Operating loss was $25.521 million against $39.293 million a year ago. Loss before income taxes was $32.516 million against $40.019 million a year ago. Loss for the period was $31.035 million against $37.804 million a year ago. Basic and diluted loss per ordinary share from continuing operations were $1.54 against $2.13 a year ago. Net cash outflow from operating activities was $25.195 million against $36.38 million a year ago. Purchase of property, plant and equipment was $0.265 million against $0.1239 million a year ago.

The company reported impairment-goodwill and long-lived intangibles was $3.36 million for the quarter ended December 31, 2016.